Combination Therapy in RCC: Expert Guidance to Individualize Treatment and Improve Outcomes

Combination Therapy in RCC: Expert Guidance to Individualize Treatment and Improve Outcomes

Monday, June 14, 2021
Webinar -- 6:30 PM ET


  • Overview of the current data on combination therapy for first-line treatment in RCC
  • Planning optimal first-line treatment for individuals with advanced or metastatic RCC: IO/IO or IO/TKI?
  • Selecting treatment for patients with progressive RCC after 1 or more previous lines of therapy
  • Management of adverse events associated with IO combinations for advanced RCC


Program Director
Eric Jonasch, MD

Associate Professor, Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Neeraj Agarwal, MD

Associate Professor of Medicine
Division of Medical Oncology
Director, GU Medical Oncology
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

Elizabeth Plimack, MD, MS

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with RCC.

Target Audience
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with RCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients most likely to benefit from immune checkpoint inhibitor–based combination therapy based on risk and biomarker assessment, along with patient medical and treatment history
  • Select optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
  • Apply clinical evidence and expert recommendations to select optimal treatment for patients with progressive RCC after 1 or more previous lines of therapy
  • Plan therapeutic strategies that optimize the sequence of therapies to provide the best possible outcome to patients with RCC
  • Manage specific disease-related complications or adverse events associated with immuno-oncology combinations for advanced RCC


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Pharmacist Continuing Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-21-037-L01-P

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at to obtain your NABP e-Profile ID.

Physician Assistant Continuing Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. Full disclosure of faculty relationships will be made prior to the activity. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.